Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data The PRISMA-IPD Statement

被引:1518
作者
Stewart, Lesley A. [1 ]
Clarke, Mike [2 ]
Rovers, Maroeska [3 ]
Riley, Richard D. [4 ,5 ]
Simmonds, Mark [1 ]
Stewart, Gavin [1 ,6 ]
Tierney, Jayne F. [7 ]
机构
[1] Univ York, Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England
[2] Queens Univ Belfast, All Ireland Hub Trials Methodol Res, Belfast, Antrim, North Ireland
[3] Radboudumc, Radbound Inst Hlth Sci, Nijmegen, Netherlands
[4] Keele Univ, Res Inst Primary Care & Hlth Sci, Keele ST5 5BG, Staffs, England
[5] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham, W Midlands, England
[6] Newcastle Univ, Ctr Rural Econ, Sch Agr Food & Rural Dev, Newcastle Upon Tyne, Tyne & Wear, England
[7] UCL, MRC Clin Trials Unit, London, England
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2015年 / 313卷 / 16期
关键词
PATIENT DATA; PREDICTION MODELS; RISK; MORTALITY; OUTCOMES; TRIALS;
D O I
10.1001/jama.2015.3656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Systematic reviews and meta-analyses of individual participant data (IPD) aim to collect, check, and reanalyze individual-level data from all studies addressing a particular research question and are therefore considered a gold standard approach to evidence synthesis. They are likely to be used with increasing frequency as current initiatives to share clinical trial data gain momentum and may be particularly important in reviewing controversial therapeutic areas. OBJECTIVE To develop PRISMA-IPD as a stand-alone extension to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) Statement, tailored to the specific requirements of reporting systematic reviews and meta-analyses of IPD. Although developed primarily for reviews of randomized trials, many items will apply in other contexts, including reviews of diagnosis and prognosis. DESIGN Development of PRISMA-IPD followed the EQUATOR Network framework guidance and used the existing standard PRISMA Statement as a starting point to draft additional relevant material. A web-based survey informed discussion at an international workshop that included researchers, clinicians, methodologists experienced in conducting systematic reviews and meta-analyses of IPD, and journal editors. The statement was drafted and iterative refinements were made by the project, advisory, and development groups. The PRISMA-IPD Development Group reached agreement on the PRISMA-IPD checklist and flow diagram by consensus. FINDINGS Compared with standard PRISMA, the PRISMA-IPD checklist includes 3 new items that address (1) methods of checking the integrity of the IPD (such as pattern of randomization, data consistency, baseline imbalance, and missing data), (2) reporting any important issues that emerge, and (3) exploring variation (such as whether certain types of individual benefit more from the intervention than others). A further additional item was created by reorganization of standard PRISMA items relating to interpreting results. Wording was modified in 23 items to reflect the IPD approach. CONCLUSIONS AND RELEVANCE PRISMA-IPD provides guidelines for reporting systematic reviews and meta-analyses of IPD.
引用
收藏
页码:1657 / 1665
页数:9
相关论文
共 35 条
  • [11] Combining multiple imputation and meta-analysis with individual participant data
    Burgess, Stephen
    White, Ian R.
    Resche-Rigon, Matthieu
    Wood, Angela M.
    [J]. STATISTICS IN MEDICINE, 2013, 32 (26) : 4499 - 4514
  • [12] THE COCHRANE-COLLABORATION - PREPARING, MAINTAINING, AND DISSEMINATING SYSTEMATIC REVIEWS OF THE EFFECTS OF HEALTH-CARE
    CHALMERS, I
    [J]. DOING MORE GOOD THAN HARM: THE EVALUATION OF HEALTH CARE INTERVENTIONS, 1993, 703 : 156 - 165
  • [13] Individual patient data meta-analyses in cancer
    Clarke, M
    Stewart, L
    Pignon, JP
    Bijnens, L
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 2036 - 2044
  • [14] Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality - An individual participant meta-analysis
    Danesh, J
    Lewington, S
    Thompson, SG
    Lowe, GDO
    Collins, R
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (14): : 1799 - 1809
  • [15] A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis
    Debray, Thomas P. A.
    Moons, Karel G. M.
    Ahmed, Ikhlaaq
    Koffijberg, Hendrik
    Riley, Richard David
    [J]. STATISTICS IN MEDICINE, 2013, 32 (18) : 3158 - 3180
  • [16] Prognosis research strategy (PROGRESS) 4: Stratified medicine research
    Hingorani, Aroon D.
    van der Windt, Danielle A.
    Riley, Richard D.
    Abrams, Keith
    Moons, Karel G. M.
    Steyerberg, Ewout W.
    Schroter, Sara
    Sauerbrei, Willi
    Altman, Douglas G.
    Hemingway, Harry
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [17] Why data sharing should be the expected norm
    Krumholz, Harlan M.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [18] Sharing Clinical Trial Data Maximizing Benefits, Minimizing Risk
    Lo, Bernard
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (08): : 793 - 794
  • [19] Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care
    Mant, J.
    Doust, J.
    Roalfe, A.
    Barton, P.
    Cowie, M. R.
    Glasziou, P.
    Mant, D.
    McManus, R. J.
    Holder, R.
    Deeks, J.
    Fletcher, K.
    Qume, M.
    Sohanpal, S.
    Sanders, S.
    Hobbs, F. D. R.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2009, 13 (32) : IX - +
  • [20] Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.i4086, 10.1136/bmj.b2700, 10.1371/journal.pmed.1000097, 10.1186/2046-4053-4-1, 10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535]